FDA, EMA workshop advances pathway for botanical medicines, BRC says
AI Summary- BRC Therapeutics participated in an FDA and EMA workshop on botanical drug development.
- BRC's Dr. Catherine Maher attended the invitation-only, limited in-person session in Amsterdam.
- BRC has commenced clinical trials for cannabinoid medicines targeting neurological and inflammatory conditions.